Piramal Pharma Solutions (PPS), a provider of contract development and manufacturing services, has launched its Xcelerate Integrated Solutions platform that provides a range of services across drug discovery, drug substance, drug product, and clinical trial services. Recently, as CMOs have developed scale and expertise across multiple verticals, customers have begun to consider ‘program based outsourcing’ in an effort to improve efficiency on time, costs, and management.
 
Xcelerate Integrated Solutions plaform is designed to offer flexibility leveraging a network of PPS sites across the globe allows customers to launch local – irrespective of whether it is North America, Europe, or Asia. The Xcelerate platform provides integrated services for orphan diseases, niche therapies, and fast track medicines, where the volume requirements are small, while having the capacity and track record to address large volume needs of metabolic diseases and neuroscience therapies. The footprint of PPS, with around half its sites in the East and the other half in the West, allows customers to manufacture the final API or Drug product out of the West, while back integrating into starting materials and intermediates out of its sites in the East.

Mr. Vivek Sharma, chief executive officer, Piramal Pharma Solutions said, “We are excited to announce the launch of the Xcelerate Integrated Solutions™ platform. This platform is a result of the growing interest from our customers on structuring preferred relationships with global leaders such as Piramal who can offer end-to-end solutions, coupled with our desire to collaborate with strategic partners.”

He added, “The Xcelerate platform sets the foundation through which customers can accelerate their programs from clinic through approval and launch. With a track record of successfully executing over 70 integrated programs in the recent past, and the associated learnings, we have now invested in capabilities and systems to provide a seamless experience to our customers.”